Skip to main content
. 2020 Jun 24;12(6):1682. doi: 10.3390/cancers12061682

Figure 3.

Figure 3

Panel (a) shows representative tumor habitat maps for a BT-474 control (CTL) and trastuzumab-treated (TRA) tumor on days 0 (pre-treatment), 1, and 4. Trastuzumab-treated tumors showed longitudinal increases in percent tumor volume (panel (b)) of the HV-HC habitat at day 4 (p = 0.02), and significantly higher percent tumor volumes of the HV-HC habitat compared to control (p = 0.03). Trastuzumab-treated tumors also showed longitudinal decreases in percent tumor volume (panel (b)) of the LV-HC habitat at day 4 (p < 0.01) and significantly lower percent tumor volumes of the LV-HC habitat compared to control (p = 0.03). Panel (c) shows representative tumor habitat maps for an MDA-MB-231 control (CTL) and low-dose albumin-bound paclitaxel (ABP-LD) tumor on days 0 (pre-treatment), 1, and 3. Low-dose ABP-treated tumors showed significant decreases in percent tumor volume (panel (d)) of the LV-HC habitat at day 1 (p < 0.01) and day 3 (p = 0.01). No significant changes were observed for control and high-dose ABP (ABP-HD) tumors over the course of the study. No significant differences were observed between treatment groups for the MDA-MB-231 cohort. Statistical significance is denoted with a * for p < 0.05 and ** for p < 0.01, error bars represent standard error.